Sign inJoin waitlistJoin the waitlist

Brian Stover

Assistant Professor · University of Florida College of Medicine

Credentials: · · · ·

History

University of Florida College of Medicine
Present

Pediatric Hematology/Oncology
University of Florida College of Medicine
2016–2019
Pediatrics
University of Florida
2013–2016
McGovern Medical School at The University of Texas Health Science Center at Houston
2009–2013
University of Florida
2005–2009

Research

RNA aggregates harness the danger response for potent cancer immunotherapy
Cell · 2024 · 121 citations
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy
Nano Letters · 2018 · 70 citations
Emerging trends in immunotherapy for pediatric sarcomas
Journal of Hematology & Oncology · 2019 · 67 citations

Elias Sayour
9 papers · 1 as a fellow
Adam Grippin
6 papers · 4 as a resident
Maryam Rahman
6 papers
John Ligon
4 papers
Natalie Silver
4 papers
SQ
Sadeem Qdaisat
4 papers
Ashley Ghiaseddin
3 papers
ER
Elizabeth Rivas
3 papers · 2 as a resident
Leighton Elliott
3 papers · 3 as a fellow
Rachel Moor
3 papers · 3 as a resident
BW
Brandon Wummer
2 papers · 1 as a resident
Jesse Kresak
2 papers

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029